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Fibroblast growth factor 23 (FGF23) regulates phosphorus
metabolism and is a strong predictor of mortality in dialysis
patients. FGF23 is thought to be an early biomarker of
disordered phosphorus metabolism in the initial stages of
chronic kidney disease (CKD). We measured FGF23 in
baseline samples from 3879 patients in the Chronic Renal
Insufficiency Cohort study, which is a diverse cohort of
patients with CKD stage 2–4. Mean serum phosphate and
median parathyroid hormone (PTH) levels were in the normal
range, but median FGF23 was markedly greater than in
healthy populations, and increased significantly with
decreasing estimated glomerular filtration rate (eGFR). High
levels of FGF23, defined as being above 100RU/ml, were
more common than secondary hyperparathyroidism and
hyperphosphatemia in all strata of eGFR. The threshold of
eGFR at which the slope of FGF23 increased was significantly
higher than the corresponding threshold for PTH based on
non-overlapping 95% confidence intervals. Thus, increased
FGF23 is a common manifestation of CKD that develops
earlier than increased phosphate or PTH. Hence, FGF23
measurements may be a sensitive early biomarker of
disordered phosphorus metabolism in patients with CKD and
normal serum phosphate levels.
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Fibroblast growth factor 23 (FGF23) regulates phosphorus
and vitamin D metabolism. In healthy individuals, FGF23 is
secreted by osteocytes in response to dietary phosphorus
loading or an increase in 1,25-dihydroxyvitamin D (1,25D)
levels, and it stimulates phosphaturia, and reduces 1,25D and
parathyroid hormone (PTH) levels.1,2 FGF23 achieves its
cellular specificity in the kidney and parathyroid glands by
binding the co-receptor klotho, which increases the affinity of
FGF23 for ubiquitously expressed FGF receptors.3 In patients
with chronic kidney disease (CKD), FGF23 levels are thought
to increase as a compensatory response to maintain normal
phosphate balance, as the capacity for renal phosphorus
excretion declines.4–6
Hyperphosphatemia is a risk factor for cardiovascular
disease and mortality and thus a potential target for
interventions to improve clinical outcomes in CKD.7
However, serum phosphate levels are normal in the vast
majority of patients with early and intermediate stages of
CKD due to compensatory increases in FGF23 and PTH.5,8
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While this limits the use of serum phosphate as an early
indicator of disordered phosphorus metabolism, it has been
proposed that FGF23 screening could identify which patients
with early-stage CKD and normal serum phosphate levels
might benefit from intervention.7 In support of this view,
high FGF23 levels are more strongly associated with kidney
disease progression, left ventricular hypertrophy, vascular
disease, and mortality than serum phosphate levels, and were
most predictive of adverse events in patients with normal
serum phosphate.9–13
Although these results are promising, critical questions
about the role of FGF23 in mineral metabolism remain
unresolved.14 For example, whether FGF23 or PTH increases
first in patients with CKD is not clear, because previous
human studies were limited by small sample size or a narrow
distribution of glomerular filtration rate (GFR).4–6 As a
result, few studies directly compared the prevalence of FGF23
excess versus secondary hyperparathyroidism within fine
strata across the spectrum of GFR. Furthermore, no large
cohort studies of CKD patients examined the impact of
dietary phosphorus intake, race, ethnicity, and socioeco-
nomic status on FGF23 levels. We measured FGF23 in
baseline samples from 3879 participants in the prospective
Chronic Renal Insufficiency Cohort (CRIC) study. The
purpose of our study was to characterize FGF23 levels in
this national multicenter, racially and ethnically diverse
population of CKD patients not yet on dialysis, to compare
the relationships of FGF23 versus PTH with declining GFR,
and to describe the relationship between FGF23, dietary
phosphorus intake, and other measures of phosphorus
metabolism across the spectrum of GFR.
RESULTS
Description of the study population
Characteristics of the 3879 CRIC participants are presented
in Table 1. The mean estimated GFR (eGFR) at the
baseline visit was 42.8±13.5ml/min per 1.73m2 and the
range was 7.0–114.0ml/min per 1.73m2; 10% of patients had
CKD stage 2, 70% stage 3, and 19% stage 4. Median
estimated daily consumption of phosphorus was 1050mg
(interquartile range (IQR): 745–1417), median 24-h urinary
phosphate excretion was 713mg (IQR: 512–953), and
median fractional excretion of phosphate (FEPi) calculated
from the 24-h specimens was 25% (IQR: 19–35). In the
overall population, mean serum phosphate (3.7±0.7mg/dl),
mean serum calcium (9.2±0.5mg/dl), and median plasma
PTH (54; IQR: 35–89 pg/ml) were within the normal range.
Among the 333 participants with available measurements,
mean 25-hydroxyvitamin D (25D) was 21±11 ng/ml, 41% of
patients had insufficient vitamin D levels (15–30 ng/ml), an
additional 35% were deficient (o15 ng/ml), and 25D levels
correlated inversely with PTH (r¼0.44, Po0.001).
The median FGF23 level was 145 RU/ml (IQR: 96–239),
which is markedly higher than levels observed in healthy
patients.15,16 When stricter criteria for CKD were applied
(eGFR o60ml/min per 1.73m2, age o70 years, and urine
albumin/creatinine ratio430mg/g), the median FGF23 rose
to 175 RU/ml (IQR: 114–289). A total of 72% of participants
met the criterion for FGF23 excess, which we defined as
X100 RU/ml. This threshold is 2.5-fold higher than the
median FGF23, and it is in the 90th percentile of the FGF23
distribution observed in previous studies of populations in
whichB80% of patients had normal kidney function (eGFR
460ml/min per 1.73m2).15,16 This threshold has also been
Table 1 | Characteristics of the study population
All participants (N=3879)
Age, years 58±11
Female, % 44.8
Black, % 41.8
Hispanic, % 12.8
Current smoker, % 13.1
Body mass index, kg/m2 32±8
Systolic blood pressure, mmHg 129±22
Hypertension, % 86.1
Diabetes, % 48.4
Phosphate binder use, % 7.0
Calcium-based binder use, % 6.6
Non-calcium-based binder use, % 0.4
Active vitamin D use, % 3.2
Vitamin D supplement use, % 10.2
Renal function
Creatinine, mg/dl 1.7±0.6
eGFR, ml/min per 1.73m2 42.8±13.5
Stage 2, % 10.3
Stage 3, % 70.1
Stage 4, % 19.4
Etiology of CKD
Diabetes, % 26.1
Hypertension, % 16.4
Other, % 13.9
Unknown, % 43.6
Laboratory results (blood)
Albumin, g/dl 3.9±0.5
Calcium, mg/dl 9.2±0.5
Phosphate, mg/dl 3.7±0.7
25D, ng/mla 21±11
1,25D, ng/mla 29±11
PTH, pg/ml 54 (35–89)
FGF23, RU/ml 145 (96–239)
Laboratory results (urine)b
24-h urinary phosphate, mg per day 713 (512–953)
Fractional excretion of phosphate, % 25 (19–35)
24-h urinary calcium, mg per day 39 (17–86)
Fractional excretion of calcium, % 0.61 (0.30–1.15)
Dietary datac
Dietary phosphorus intake, mg per day 1050 (745–1417)
Dietary calcium intake, mg per day 615 (422–870)
Total caloric intake, kcal per day 1626 (1214–2267)
Abbreviations: CKD, chronic kidney disease; eGFR, estimated glomerular filtration
rate; FGF, fibroblast growth factor; PTH, parathyroid hormone; 1,25D, 1,25-
dihydroxyvitamin D; 25D, 25-hydroxyvitamin D.
Values are %, means±s.d., medians (interquartile range).
a25D and 1,25D levels were available in 333 and 332 participants, respectively.
b24-h urinary data were available for 3659 participants.
cDietary data were available for 2797 participants.
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associated with CKD progression, cardiovascular disease, and
mortality in previous prospective studies of CKD patients.9,13
Using an even more conservative threshold of X125 RU/ml
to define FGF23 excess, 59% of participants qualified.
Consistent with previous reports,4,5 the strongest univariate
correlate of FGF23 was eGFR (r¼ –0.52, Po0.0001). FGF23
also correlated directly with PTH (r¼ 0.37, Po0.0001) and
serum phosphate (r¼ 0.35, Po0.0001), and inversely with
1,25D (r¼ –0.26, Po0.0001), in the 332 participants for
whom these levels were available. Each of these associations
remained significant after adjusting for eGFR. While there
was no significant relationship with 24-h urinary phosphate
when adjusted for eGFR, higher FGF23 was linearly associated
with FEPi (r¼ 0.25, Po0.0001). Additional factors associated
with a higher FGF23 adjusted for eGFR included younger age,
female gender, black race, and lower annual income (Po0.008
for each).
Mineral metabolites in relation to GFR
Table 2 presents the interrelationships between mineral
metabolites and renal function after dividing the cohort into
seven fine strata of descending eGFR. Beginning at an eGFR
o60ml/min per 1.73m2, serum phosphate, PTH, and FGF23
levels increased in each consecutive stratum of descending
eGFR. Similarly, the prevalence of hyperphosphatemia
(phosphate X4.6mg/dl), secondary hyperparathyroidism
(PTH X65pg/ml), and FGF23 excess (FGF23 X100RU/ml)
increased progressively with declining eGFR (Figure 1).
Consistent with previous reports,8 hyperphosphatemia was
a late manifestation of CKD, as the prevalence first exceeded
10% in patients with eGFR o39ml/min per 1.73m2. In
contrast, abnormalities in FGF23 levels were an early finding.
At an eGFR of 50–59ml/min per 1.73m2, 450% of patients
had an FGF23 X100 RU/ml when only 3% were hyper-
phosphatemic and only 22% manifested secondary hyper-
parathyroidism. Among participants with eGFRX70ml/min
per 1.73m2, 33% had FGF23 levels X100 RU/ml. Given the
imprecision of eGFR, especially among individuals with
mostly preserved renal function,17 we reevaluated the above
relationships in the subset of participants (N¼ 1434) who
underwent direct GFR measurements with 125-I iothalamate
clearance (iGFR). Estimated GFR and iGFR were highly
correlated (r¼ 0.82, Po0.0001), hence the results conveyed
in Table 2 and Figure 1 were qualitatively unchanged when
analyzed according to iGFR.
Estimated daily dietary phosphorus intake was qualita-
tively similar across the spectrum of eGFR and did not
correlate significantly with FGF23, phosphate, or PTH levels.
FEPi increased but total 24-h urinary phosphate excretion
decreased with decreasing strata of eGFR (Table 2). Similarly,
the ratio of 24-h urinary phosphate excretion/estimated daily
dietary phosphorus intake decreased from 470% in
participants with eGFR 439ml/min per 1.73m2 to 53% in
those with eGFR o20ml/min per 1.73m2. This decrease
coincided with the gradual increase in serum phosphate
levels. T
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Relationships of FGF23 and PTH with eGFR
To further compare the relative prevalence of abnormally
high FGF23 versus PTH levels across the spectrum of eGFR,
we calculated the proportions of participants with normal or
high FGF23 and PTH levels within each eGFR category
(Figure 2). As expected, the most common pattern in the
strata of more preserved eGFR was normal FGF23/normal
PTH, whereas high FGF23/high PTH was predominant in the
lower eGFR strata. In the intermediate eGFR range of
30–60ml/min per 1.73m2, an isolated increase in FGF23 was
the most common pattern and was far more likely than an
isolated increase in PTH, which was the rarest combination
in all eGFR categories. For example, among participants with
eGFR 30–60ml/min per 1.73m2 and an FGF23X100 RU/ml,
only 40% met criteria for secondary hyperparathyroidism,
whereas among those with established secondary hyperpar-
athyroidism, FGF23 wasX100 RU/ml in 85% of participants.
Indeed, in the overall population, the combination of high
FGF23/normal PTH was 6.4–fold more prevalent than
normal FGF23/high PTH (Po0.0001). Using a more
conservative cut-point of X125 RU/ml to define FGF23
excess did not qualitatively alter the results: the combination
of high FGF23/normal PTH remained 2.8-fold more
prevalent than normal FGF23/high PTH (Po0.0001). The
results were also unchanged when defining secondary
hyperparathyroidism based on the 1–84 PTH assay and
its upper limit of 36 pg/ml.18 Excluding participants treated
with phosphate binders, active vitamin D, or vitamin D
supplements did not alter these findings. The relationships
between eGFR and mineral metabolites did not vary by sex
or race.
Finally, we plotted FGF23 and PTH versus eGFR expressed
on a continuous scale using cubic splines, and estimated the
eGFR threshold at which there was a statistically significant
increase in the slope of each hormone. As shown in Figure 3a
and b, the slope of the FGF23 curve increased at an eGFR
threshold of 57.8ml/min per 1.73m2 (95% confidence
interval: 55.4–60.8), which was significantly higher (based
on non-overlapping 95% confidence intervals) than the
comparable threshold for PTH of 46.9ml/min per 1.73m2
(95% confidence interval: 45.5–51.4). Adjustment for age and
fasting status did not change the results. In aggregate, these
data suggest that FGF23 increases earlier in the course of
CKD than PTH.
Serum and urinary phosphate in relation to eGFR
Next, we plotted serum phosphate and urinary FEPi in
relation to eGFR using fitted splines and tested whether there
were thresholds of eGFR at which there was a statistically
significant change in their slopes (Figure 4). Log FEPi
increased uniformly across the spectrum of decreasing eGFR
without a detectable threshold. In contrast, serum phosphate
demonstrated a J-shaped curve: levels declined (slope
¼0.017±0.002) between the upper range of eGFR through
an eGFR of 59.1ml/min per 1.73m2 (95% confidence
0
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Figure 1 |Prevalence of hyperphosphatemia, secondary
hyperparathyroidism, and elevated fibroblast growth factor
23 (FGF23) in relation to estimated glomerular filtration
rate (eGFR). Hyperphosphatemia was defined as serum
phosphate X4.6mg/dl, secondary hyperparathyroidism as
parathyroid hormone (PTH) X65 pg/ml, and FGF23 excess as
FGF23 X100 RU/ml.
eGFR < 20
eGFR 20–29
eGFR 30–39
eGFR 40–49
eGFR 50–59
eGFR 70
eGFR 60–69
CKD stage 4 CKD stage 3 CKD stage 2
High FGF23/normal PTH
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Figure 2 |Proportions of participants with normal or high
fibroblast growth factor 23 (FGF23) and parathyroid hormone
(PTH) levels within each estimated glomerular filtration rate
(eGFR) category. Sections of pie charts indicate proportions of
individuals with FGF23 and/or PTH abnormalities by eGFR
category. White: normal PTH and FGF23 levels; yellow: high PTH/
normal FGF23; gray: high FGF23/high PTH; and blue: high FGF23/
normal PTH. CKD, chronic kidney disease.
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interval: 48.6–63.9), whereas below an eGFR of 59.1, serum
phosphate increased (slope ¼ þ 0.067±0.003). The results
remained unchanged following adjustment for age and
fasting status. These data are consistent with the subtle
decrease in serum phosphate levels in the stratum with eGFR
of 60–69ml/min per 1.73m2 compared with the adjacent
higher and lower strata (Table 2). Furthermore, when
juxtaposed with data in Table 2, these results suggest two
phases in the serum phosphate curve (Figure 4). In the
proposed first phase (eGFR 459.1ml/min per 1.73m2), the
subtle reduction in serum phosphate levels was observed in
association with increased FGF23 and FEPi, and decreased
1,25D levels. In the proposed second phase (eGFRo59.1ml/min
per 1.73m2), serum phosphate levels gradually increased
from their nadir whereas FGF23 increased more sharply, FEPi
continued to increase, and 1,25D decreased further.
DISCUSSION
In this study of nearly 4000 CKD patients, the largest human
study of FGF23 to date, we validate that FGF23 is elevated in
CKD patients, increases as eGFR falls, and both FGF23 and
PTH increase before hyperphosphatemia first appears.4–6
Despite being limited by its cross-sectional design and
incomplete vitamin D data, our study suggests that FGF23
excess may be the earliest bellwether of disordered mineral
metabolism in CKD.
Although levels of FGF23 and PTH are each markedly
increased in advanced renal failure,5,8 the results of this study
suggest that the increase in FGF23 precedes that of PTH. As
expected, both FGF23 and PTH were elevated in most
patients with extremely low eGFR, and many patients with
the most preserved eGFR had normal levels of each. However,
an increased FGF23 in the setting of a normal PTH was 46
times more likely than an isolated increase in PTH.
Furthermore, the slope of FGF23 versus eGFR turned
upwards at a significantly higher eGFR than the comparable
threshold for PTH. Importantly, vitamin D deficiency,
which is known to raise PTH, was present in 76% of
participants and was inversely correlated with PTH. The
finding that PTH rises after FGF23 despite the high frequency
of vitamin D deficiency further supports the temporal sequence
we propose. Nonetheless, 5.8% of participants had isolated
PTH elevations, suggesting that additional FGF23-independent
factors drive an initial increase in PTH in certain CKD
patients.
Although the weight of evidence favors FGF23 elevation as
the upstream pathophysiological event that lowers 1,25D and
thus increases PTH, as was recently shown in elegant
experiments using an animal model of CKD and anti-
FGF23 antibodies,19 the primary stimulus for enhanced
FGF23 secretion in early CKD is less clear. On the basis of
scant human and experimental data, it has been proposed
that decreased expression of klotho may be one step further
upstream from FGF23 excess.20 Indeed, parathyroid resis-
tance to the inhibitory effects of FGF23 is mediated, in part,
by downregulation of klotho.21–23 However, if klotho
deficiency is the primary factor that causes renal resistance
to FGF23 and drives secondary, appropriate increases in
FGF23 secretion, CKD patients should manifest at least subtle
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signs of klotho deficiency early in the course of their disease:
modest increases in serum phosphate, 1,25D and calcium
levels. On the contrary, increases in 1,25D and serum calcium
are not observed in early CKD, and we and others observed a
modest reduction in serum phosphate during early CKD.24,25
This decrement was accompanied by elevated FGF23 and
FEPi and lower 1,25D levels, a constellation of metabolic
changes that characterize syndromes of primary FGF23
excess, such as X-linked hypophosphatemia,26 but not
syndromes of primary klotho deficiency.27 An alternative,
unifying explanation is that the initial increase in FGF23 in
early CKD causes secondary downregulation of klotho,
perhaps in response to relative hypophosphatemia or reduced
1,25D, which is known to regulate klotho expression.28
Indeed, in transgenic mice engineered to overproduce FGF23,
klotho was the most significantly inhibited transcript.29
Although we were not able to measure klotho levels, the
pattern of metabolic changes that we observed suggests that
increased FGF23 precedes klotho deficiency.
It has also been postulated that FGF23 increases in CKD as
an appropriate response to minimize ‘phosphate retention’,
but our data suggest other possible factors. The early
reduction in serum phosphate levels in association with
already elevated FGF23 levels (proposed phase 1) suggests
that perhaps renal injury itself may be an initial stimulus for
FGF23 secretion in early CKD by causing increased produc-
tion of a factor that stimulates FGF23 secretion or decreased
expression of a tonic inhibitor. Animal studies in which
FGF23 rose immediately after the kidney was injured but
before any increase in serum phosphate support this
possibility,19 as do human data that reported an upwards
inflection in FGF23 levels as early as an eGFR of 90ml/min
per 1.73m2,30 and our finding that 33% of participants with
an eGFR X70ml/min per 1.73m2 had FGF23 levels
X100 RU/ml. Furthermore, patients with autosomal domi-
nant polycystic kidney disease and preserved eGFR exhibited
elevated FGF23 levels and subtly reduced serum phosphate
levels,31 which is consistent with our results.
Below an eGFR of 60ml/min per 1.73m2, serum
phosphate rose gradually (proposed phase 2) concurrent
with a decrease in the ratio of 24-h phosphate excretion/
estimated daily phosphorus intake. Though we only had data
from a single 24-h urine collection and dietary assessment,
and we did not have 1,25D measurements in the entire
cohort, several possibilities may explain this finding. First,
serum phosphate could have risen with declining eGFR as a
simple adaptation to increase the filtered load of phosphate
to overcome the partially reduced capacity for urinary
excretion, as has been previously described.32 This construct
implies the maintenance of even phosphate balance at the
cost of a modest increase in serum levels. Second, the eGFR-
dependent, progressive reduction in the ratio of phosphorus
excretion/intake could reflect a gradual reduction in the
percent of ingested phosphorus that was absorbed, as
has been reported previously.33–35 This would also imply
even phosphate balance and could occur through direct
FGF23-dependent inhibition of sodium-phosphate transpor-
ters in the gut,36 FGF23-mediated reductions in 1,25D levels
that decrease vitamin D-dependent phosphorus absorption,
or reduced vitamin D-dependent calcium absorption that
leads to an increase in luminal calcium that acts as an
endogenous phosphate binder to limit absorption.37 Third, if
the percent of dietary phosphorus intake that was absorbed
remained constant as eGFR declined, then the lower 24-h
excretion would signify positive phosphate balance that was
reflected in the modest increase in serum phosphate. This
paradigm would entail progressive total body phosphate
overload, beginning in late stage 3–4, as has been commonly
assumed but contradicted by classic balance studies.38,39
Deciphering these possibilities will require detailed balance
studies across a range of eGFR.
Not all of the CKD patients had elevated FGF23 levels, and
there was significant variability across the spectrum of eGFR.
Some of this heterogeneity may be because of unknown
physiological or genetic factors,40 but our finding that lower
income was associated with higher FGF23 independent of
eGFR suggests important environmental factors. We pre-
viously reported that poverty was independently associated
with higher serum phosphate levels in CKD and non-CKD
patients, and speculated that this may be because of
impoverished individuals disproportionately consuming ex-
cessive amounts of cheap, processed foods laden with highly
bioavailable phosphorus-rich additives.41,42 The independent
association between poverty and increased FGF23 supports
this hypothesis. On the basis of these data and the published
literature, we propose that the heterogeneous distribution of
FGF23 levels across CKD patients likely results from a
combination of fixed genetic determinants, the severity of
kidney disease, and modifiable components, such as dietary
phosphorus intake.
The recent observation that even small increments in
serum phosphate are independently associated with adverse
renal and cardiovascular events43,44 has sparked intense
interest in initiating treatment of disordered phosphorus
metabolism earlier in the course of CKD. While additional
work is needed to establish physiologically based normal
ranges of FGF23 and threshold levels that predict clinically
meaningful outcomes, FGF23 has the potential to be a novel,
easily measurable biomarker to help guide the efficient design
of randomized controlled trials to determine whether early
initiation of therapy with phosphate binders and dietary
phosphorus restriction will improve clinical outcomes in
CKD.7 In support of this approach, previous data demon-
strated that FGF23 is a powerful prognostic predictor of
adverse clinical outcomes in CKD9–13 and that dietary
phosphate binders can lower FGF23 in this population.45
The current study offers additional important insight into
the design of a clinical outcomes trial targeting phosphorus
metabolism in early CKD. On the basis of the results of
this study, we propose that patients with the triad of
eGFR o60ml/min per 1.73m2, FGF23 X100 RU/ml, and
serum phosphate X3.5mg/dl would be ideal candidates
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most likely to benefit from interventions targeting phosphorus
metabolism.
MATERIALS AND METHODS
Description of cohort
CRIC is a multicenter prospective cohort study of risk factors for
cardiovascular disease and progression of CKD.46 Additional
Hispanic participants were enrolled in the ancillary Hispanic CRIC
study to distinguish CRIC as the largest, most racially and ethnically
diverse CKD cohort available to date. Adult patients aged 21–74
years with mild to moderate CKD, defined as an age-stratified eGFR
at the screening visit between 20–70ml/min per 1.73m2, were
enrolled. Individuals who were eligible based on their screening
eGFR but whose eGFR at the first study visit was found to be outside
the range of 20–70ml/min per 1.73m2 were retained in the study.
Patients were excluded for pregnancy, New York Heart Association
class III–IV heart failure, HIV, cirrhosis, myeloma, renal cancer,
recent chemotherapy or immunosuppressive therapy, polycystic
kidney disease, organ transplantation, or previous treatment with
dialysis for 41 month. The CRIC protocol was approved by the
institutional review boards at each of the seven primary sites. All
participants provided written informed consent.
Study population
We evaluated 3879 of the 3939 total CRIC and Hispanic CRIC
participants who had baseline plasma FGF23 measurements. The
mean eGFR of the 60 participants for whom FGF23 measurements
were not available did not differ significantly from levels of those
included in this analysis (45.0±13.5 versus 42.8±13.5ml/min per
1.73m2). Dietary data were available for 2797 participants. The
remainder either did not complete the food frequency questionnaire
or their data were excluded by the CRIC data-coordinating center
because of implausible values for total energy intake. The 24-h
urinary data were available for 3659 participants. Serum 25D and
1,25D levels were available in a subset of 333 and 332 participants,
respectively. A subset of 1434 participants had GFR measured
directly using 125-I iothalamate clearance (iGFR).
Data collection and measurements
We analyzed the following data that were collected at the baseline
visit: demographics, medical history, use of phosphate binders,
vitamin D supplements and active vitamin D analogs, blood
pressure, anthropometry, fasting blood samples, 24-h urine speci-
mens, and estimated dietary phosphorus, calcium, and caloric
intake from the National Cancer Institute’s Diet History Ques-
tionnaire.47 Annual household income was self-reported and
categorized as o$20,000 per year, $20,001 to $50,000 per year, or
4$50,000 per year.
Comprehensive metabolic panels and urinary biochemical panels
were measured using standard assays. In addition to total 24-h
urinary phosphate excretion (mg/day), we analyzed urinary FEPi
((urine phosphate  serum creatinine)/(serum phosphate  urine
creatinine)  100%). The latter corrects for over- or under-
collections of 24-h urine samples and standardizes urinary
phosphate excretion to the degree of renal dysfunction, which is
important in CKD cohorts. Plasma FGF23 was measured using the
second generation C-terminal assay that detects two epitopes in the
C-terminus of FGF23 (Immutopics, San Clemente, CA; coefficient
of variation o5%). C-terminal and intact FGF23 assays are highly
correlated in CKD,10 and a recent report of peritoneal dialysis
patients that used an in vitro reporter assay suggested that virtually
all circulating FGF23 was intact, biologically active, and accurately
measured by either assay.48 Plasma PTH was measured using a total
PTH assay, which includes the 1–84 PTH molecule and 7–84
fragments (Scantibodies, Santee, CA; coefficient of variationo5%).
Results from the 1–84 PTH assay were used in secondary analyses.
Serum 25D was quantified by radioimmunoassay (Diasorin,
Stillwater, MN; coefficient of variation o3%) and serum 1,25D
was measured by competitive chemiluminescent immunoassay
(Heartland Assays, Ames, IA; coefficient of variation o12%).
Statistical analysis
We evaluated the univariate and eGFR-adjusted correlations
between FGF23 and other mineral metabolites using Spearman
correlation and linear regression. We performed descriptive analyses
of mineral metabolites in the overall population and after
categorizing participants into seven fine categories of eGFR (o20,
20–29, 30–39, 40–49, 50–59, 60–69, X70ml/min per 1.73m2). We
compared mean (median) values within each group to that in the
eGFR 470ml/min per 1.73m2 stratum with the use of t-tests or
Wilcoxon tests, as appropriate. We defined hyperphosphatemia as
serum phosphate X4.6mg/dl,8 secondary hyperparathyroidism as
PTH X65 pg/ml,8 and FGF23 excess as FGF23 X100RU/ml.
Because normal reference values for FGF23 in healthy subjects with
sufficient vitamin D levels are not available, we used the FGF23
threshold that was 2.5-fold higher than the median FGF23 and in
the 90th percentile of the FGF23 distribution in previous studies of
populations in which B80% of patients had normal kidney
function (eGFR 460ml/min per 1.73m2).15,16 We estimated the
prevalence of abnormally high values of FGF23, PTH, and serum
phosphate, and calculated the proportions of participants with
either isolated increases in FGF23 or PTH, abnormally high values of
both hormones, or normal values of both within each of the seven eGFR
categories. We calculated the probability of an elevated FGF23 when
PTH levels were o65pg/ml and, conversely, the probability of an
elevated PTH when FGF23 levels were o100RU/ml. We compared
proportions using w2-tests. In additional sensitivity analyses, we repeated
the probability calculations while excluding individuals treated with
vitamin D supplements, phosphate binders, and active vitamin D, after
substituting FGF23 X125RU/ml as the FGF23 cut-point, and PTH
436pg/ml as the cut-point for the 1–84 PTH assay.18 We also repeated
the main analyses in the subcohort of participants with iGFR.
We used cubic spline regression to fit separate curves for the
relationships of log-transformed FGF23 and PTH, with eGFR as
the independent variable, and used a bootstrapping procedure to
determine the eGFR thresholds at which the slope of FGF23 and
PTH became steeper, as described elsewhere.49 We estimated the
value for this threshold as the minimizer of the profile residual sum
of squares, as has been done previously.50 To explore the relationship
of serum phosphate and FEPi with eGFR, we used similar methods
to test for and estimate the threshold of eGFR at which serum
phosphate and FEPi change. Because the fitted spline for serum
phosphate displayed a J-shaped pattern, we tested whether there was
an eGFR threshold at which the direction of the slope changed.
Because eGFR criteria for inclusion were age-stratified, and fasting
status can affect levels of mineral metabolites, we performed
additional sensitivity analyses that adjusted the spline models for
age and fasting status. P-values o0.05 were considered statis-
tically significant. We performed analyses using SAS, version 9.2
(SAS Institute, Cary, NC) and R, Version 2.11.1 (R Foundation for
Statistical Computing, Vienna, Austria).
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